Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. Global Chief Commercial Officer John Leite reported an open-market sale of 13,975 shares of common stock on June 4, 2026 at a weighted average price of about $50.07 per share, executed under a pre-arranged Rule 10b5-1 plan. On June 2, 2026, 4,059 shares were withheld to satisfy tax obligations from vesting restricted stock units, which was not a market sale. Following these transactions, Leite directly holds 132,305 shares of Veracyte common stock.
VCYT related filing reports an intended resale of common stock by an issuer representative and recent 10b5-1 sales by an individual. The filing lists 3176 shares of Common stock described as Restricted Stock Units with an offering date of 06/02/2026. It also records a 10b5-1 sale of 10,204 shares on 05/06/2026 generating $398,211.10.
VERACYTE, INC. Vice President and Chief Accounting Officer Jonathan Wygant reported an exercise-and-sell transaction in company stock. On May 22, 2026, he exercised stock options for 24,000 shares of common stock at $24.80 per share, then sold 24,000 shares of common stock in an open-market sale at a weighted average price of $45.401 per share, with individual sale prices ranging from $45.07 to $45.69. Following these transactions, he directly owns 45,434 shares of Veracyte common stock. The option exercised is reported as fully vested and, after exercise, no remaining shares from that option grant are outstanding.
VERACYTE, INC. director Robert S. Epstein reported an open-market sale of 10,000 shares of common stock on May 20, 2026 at a weighted average price of $44.01 per share, with individual sale prices ranging from $44.00 to $44.10.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these sales, Epstein directly owns 52,446 shares of Veracyte common stock.
Veracyte, Inc. ownership disclosure: Artisan Partners entities report beneficial ownership of 5,496,370 shares of common stock, representing 6.9% of the class based on 79,458,427 shares outstanding as of 02/20/2026. The filing attributes 4,889,589 shares to shared voting power and 5,496,370 shares to shared dispositive power. The shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership and are reported through a joint filing executed 05/13/2026.
State Street Corporation reported beneficial ownership of 5,043,590 shares of Veracyte Inc. common stock, representing 6.3% of the class as of 03/31/2026. The filing lists shared voting power of 4,800,493 shares and shared dispositive power of 5,043,590 shares. The filing identifies several State Street advisory subsidiaries as holders of the position.